SubsidieMeestersDiagnostics of aberrant cancer glycosylation signatures
The project aims to develop high-specificity antibodies targeting cancer-associated carbohydrate-neoantigens for early cancer diagnosis and personalized therapy optimization.
Projectdetails
Introduction
Cancer is a leading cause of death worldwide and novel diagnostic and therapeutic approaches are much needed. All living cells are covered with a dense layer of ‘sugar-coat’ that is altered in cancer.
Aberrant Glycosylation Patterns
One of the hallmarks of cancer is the expression of aberrant cell surface glycosylation patterns compared to normal cells. Current antibody-based assays against cancer glycans are commonly utilized to monitor clinical response to therapy.
Limitations of Current Assays
However, none of these assays are useful for early detection or diagnosis due to low sensitivity and specificity.
Project Aim
We aim to develop cancer diagnostics based on signatures of carbohydrate-neoantigens.
Unique Antibody Generation System
We developed a unique system to generate potent antibodies of high specificity and affinity against various cancer glycans. Such potent antibodies that recognize tumor-associated carbohydrate-neoantigens can potentially be used as novel cancer diagnostics.
Potential Impact
Such validated tools could be used to identify cancer at an early stage and also for optimizing therapy for patients with unique sugar-code signatures.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-7-2022 |
| Einddatum | 31-12-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- TEL AVIV UNIVERSITYpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Engineering CAR-T cells to overcome glycosylation-driven tumour resistanceThe project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers. | ERC STG | € 1.500.000 | 2023 | Details |
Targeting of glycosylation pathways to empower CAR-T therapy of solid tumors.This project aims to enhance CAR-T cell therapy for solid tumors by engineering glycosylation pathways to improve immune response and long-term persistence against immunosuppressive environments. | ERC ADG | € 2.498.435 | 2023 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanningProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly. | EIC Accelerator | € 1.987.387 | 2021 | Details |
Engineering CAR-T cells to overcome glycosylation-driven tumour resistance
The project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers.
Targeting of glycosylation pathways to empower CAR-T therapy of solid tumors.
This project aims to enhance CAR-T cell therapy for solid tumors by engineering glycosylation pathways to improve immune response and long-term persistence against immunosuppressive environments.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning
ProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly.